<DOC>
	<DOCNO>NCT00006239</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Tretinoin may help hematologic cancer cell develop normal white blood cell . PURPOSE : Phase I trial study effectiveness combine phenylbutyrate tretinoin treat patient hematologic cancer .</brief_summary>
	<brief_title>Phenylbutyrate Tretinoin Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety toxicity phenylbutyrate tretinoin patient myelodysplastic syndrome , chronic myelomonocytic leukemia , acute myeloid leukemia . - Determine pharmacokinetic interaction regimen patient . - Determine potential therapeutic activity regimen patient . OUTLINE : This dose escalation study tretinoin . Patients receive phenylbutyrate IV continuously day 1-7 week 1 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 . Patients also receive oral tretinoin three time daily day 1-7 week 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tretinoin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose limit toxicity . An additional cohort 6 patient accrue MTD . These patient receive phenylbutyrate IV continuously day 1-3 week 1 3-18 . These patient also receive oral tretinoin three time daily day 1-3 week 2-18 . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-24 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm myelodysplastic syndrome ( MDS ) Refractory anemia Primary refractory leukopenia thrombocytopenia morphologic feature MDS Refractory anemia excess blast ( RAEB ) Refractory anemia ring sideroblast RAEB transformation Must excess blast hematopoietically compromise , define one following : RBC transfusion dependent Granulocyte count le 1,000/mm^3 Platelet count le 50,000/mm^3 OR Diagnosis chronic myelomonocytic leukemia Hematopoietically compromise ( define ) OR Excess blast OR Evaluable disease relate symptomatology ( organomegaly leukemia cutis ) OR Diagnosis acute myeloid leukemia WBC le 20,000/mm^3 stable least 2 week Unlikely require cytotoxic therapy study No CNS pulmonary leukostasis CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hemoglobin least 8 g/dL ( transfusion allow ) No disseminated intravascular coagulation Hepatic : Bilirubin le 2.0 mg/dL ( unless due hemolysis Gilbert 's syndrome ) Renal : Creatinine le 2.0 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 week prior , , 3 month study No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 3 week since prior biologic therapy , include hematopoietic growth factor , recover Chemotherapy : See Disease Characteristics At least 3 week ( 1 month MDS patient ) since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>